Skip to Main
Investment Banking

Joint Bookrunner on Capricor Therapeutics' Public Offering of Common Stock

  • Oppenheimer & Co. Inc.
  • October 21, 2024
Oppenheimer &. Co. Inc. acted as Joint Bookrunner on Capricor Therapeutics’ $86.3MM Confidentially Marketed Public Offering of Common Stock

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced the closing of its previously announced underwritten public offering of 5,073,800 shares of its common stock, including the exercise in full of the underwriters’ option to purchase additional shares to cover over allotments, bringing the total gross proceeds to Capricor from the offering to approximately $86.3 million, before deducting underwriting commissions and other offering expenses payable by Capricor. All of the shares of common stock sold in the offering, including the over-allotment, were offered by Capricor. The closing of the offering occurred on October 18, 2024.

capricor deal
capricor deal

Piper Sandler & Co. and Oppenheimer & Co. Inc. acted as the joint book-running managers for the offering.

The Company intends to use the net proceeds from this offering on the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes.

Michael Margolis
Name:

Michael A. Margolis, R.Ph.

Title:

Senior Managing Director, Head of Healthcare, Head of Healthcare Life Sciences

Address

85 Broad Street
23rd Floor
New York, NY 10004Click to open address in a new window on Google Maps

Contact

(212) 667-7622 MichaelA.Margolis@opco.com
Hide Bio
Name: Title:
Hide Bio

DISCLOSURES

This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2024 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 7203892.1